Material and Methods: Files of twenty-nine patients with CD diagnosed between June 1997 and April 2015 were reviewed retrospectively. Clinical features, treatment alternatives and results were evaluated.

Results: Twenty- fi ve patients were male and four female. Mean age of the subjects was 10,3±13.9 (Range: 1 month-56 years) and mean follow up time was 2.8±3.1 years (Range; 6 month -14years). Thirty eyes of 29 patients were involved in the study. The involvement was unilateral in 28 patients and bilateral in one patient. Twelve of 30 eyes (40%) were diagnosed to have stage 2 disease, 9 eyes (30%) stage 3, 5 eyes (16.6%) stage 4 and 4 eyes (13.3%) had stage 5 disease. Where 12 of 21 eyes diagnosed to have stage 2 or 3 disease were received photocoagulation combined with adjuvant therapy (intravitreal injection), 9 eyes were treated with only laser photocoagulation therapy. While eyes diagnosed to have stage 4 disease were followed up without any treatment, one of the eyes which diagnosed to have stage 5 disease, enucleation surgery was performed for defi nitive diagnosis from retinablostoma. Evisceration surgery was performed to the other one because of painful eye due to CH. Best-corrected visual acuity did not change in 9 eyes, decreased in 8 eyes and increased only in 4 eyes diagnosed to have stage 2 or 3 disease at the end of the last visit.

Conclusion: Successful visual outcome usually depends on the disease stage in eyes with CD. Although laser photocoagulation and cryotherapy are the main treatment modalities in early stages of the disease, intravitreal steroid and anti- vascular endothelial growth factor injections in addition to ablative therapy may help to achieve better anatomical and visual outcome. Keywords : Afl ibercept, bevacizumab, coats? disease, dexamethasone implant, ranibizumab